Ken Griffin Geron Corp Transaction History

Citadel Advisors LLC

$559 Billion
Q4 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Geron Corp stock. As of the latest transaction made, Citadel Advisors LLC holds 252,700 shares of GERN stock, worth $429,590. This represents 0.0% of its overall portfolio holdings.

Number of Shares

252,700

Previous 211,100 19.71%

Holding current value

$429,590

Previous $958,000 6.68%

% of portfolio

0.0%

Previous 0.0%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	$3.3 - $4.44 $1.65 Million - $2.22 Million	-500,187 Reduced 10.68%	4,184,145 $14.8 Million
Q3 2024 Nov 14, 2024	BUY	$4.17 - $4.99 $10.1 Million - $12.1 Million	2,417,429 Added 106.64%	4,684,332 $21.3 Million
Q2 2024 Aug 14, 2024	BUY	$3.1 - $5.09 $3.97 Million - $6.52 Million	1,280,794 Added 129.88%	2,266,903 $9.61 Million
Q1 2024 May 15, 2024	BUY	$1.75 - $3.44 $600,153 - $1.18 Million	342,945 Added 53.32%	986,109 $3.25 Million
Q4 2023 Feb 14, 2024	BUY	$1.74 - $2.31 $437,531 - $580,861	251,455 Added 64.19%	643,164 $1.36 Million
Q3 2023 Nov 14, 2023	SELL	$2.11 - $3.28 $4.77 Million - $7.42 Million	-2,262,062 Reduced 85.24%	391,709 $830,000
Q2 2023 Aug 14, 2023	SELL	$1.97 - $3.69 $8.34 Million - $15.6 Million	-4,235,032 Reduced 61.48%	2,653,771 $8.52 Million
Q1 2023 May 15, 2023	BUY	$2.14 - $3.4 $14.1 Million - $22.3 Million	6,569,096 Added 2054.72%	6,888,803 $14.9 Million
Q4 2022 Feb 14, 2023	SELL	$2.03 - $2.42 $1.75 Million - $2.09 Million	-862,123 Reduced 72.95%	319,707 $773,000
Q3 2022 Nov 14, 2022	BUY	$1.67 - $2.94 $1.8 Million - $3.17 Million	1,079,033 Added 1049.67%	1,181,830 $2.77 Million
Q2 2022 Aug 15, 2022	SELL	$1.19 - $1.65 $320,302 - $444,117	-269,162 Reduced 72.36%	102,797 $160,000
Q1 2022 May 16, 2022	BUY	$0.99 - $1.6 $35,212 - $56,908	35,568 Added 10.57%	371,959 $506,000
Q4 2021 Feb 14, 2022	BUY	$1.22 - $1.72 $189,884 - $267,705	155,643 Added 86.11%	336,391 $410,000
Q3 2021 Nov 15, 2021	SELL	$1.2 - $1.5 $39,345 - $49,182	-32,788 Reduced 15.35%	180,748 $248,000
Q2 2021 Aug 16, 2021	BUY	$1.25 - $1.83 $158,416 - $231,921	126,733 Added 146.0%	213,536 $301,000
Q1 2021 May 17, 2021	BUY	$1.52 - $2.1 $95,276 - $131,632	62,682 Added 259.86%	86,803 $137,000
Q4 2020 Feb 16, 2021	SELL	$1.55 - $2.05 $281,213 - $371,927	-181,428 Reduced 88.27%	24,121 $38,000
Q3 2020 Nov 16, 2020	SELL	$1.59 - $2.19 $55,298 - $76,166	-34,779 Reduced 14.47%	205,549 $358,000
Q2 2020 Aug 14, 2020	SELL	$1.05 - $2.18 $60,862 - $126,361	-57,964 Reduced 19.43%	240,328 $524,000
Q1 2020 May 15, 2020	BUY	$0.89 - $1.49 $34,209 - $57,272	38,438 Added 14.79%	298,292 $355,000
Q4 2019 Feb 14, 2020	BUY	$1.27 - $1.54 $228,914 - $277,581	180,248 Added 226.43%	259,854 $353,000
Q3 2019 Nov 14, 2019	SELL	$1.15 - $1.59 $69,439 - $96,007	-60,382 Reduced 43.13%	79,606 $105,000
Q2 2019 Aug 14, 2019	SELL	$1.37 - $2.02 $76,726 - $113,130	-56,005 Reduced 28.58%	139,988 $197,000
Q1 2019 May 15, 2019	BUY	$1.01 - $1.83 $9,578 - $17,355	9,484 Added 5.09%	195,993 $0
Q4 2018 Feb 14, 2019	SELL	$0.98 - $1.85 $1.11 Million - $2.09 Million	-1,132,205 Reduced 85.86%	186,509 $186,000
Q3 2018 Nov 13, 2018	BUY	$1.76 - $6.38 $1.92 Million - $6.97 Million	1,093,063 Added 484.4%	1,318,714 $0
Q2 2018 Aug 10, 2018	BUY	$3.29 - $4.82 $578,934 - $848,165	175,968 Added 354.18%	225,651 $0
Q1 2018 May 11, 2018	SELL	$1.81 - $5.98 $711,941 - $2.35 Million	-393,338 Reduced 88.79%	49,683 $211,000
Q4 2017 Feb 09, 2018	SELL	$1.8 - $2.32 $199,648 - $257,325	-110,916 Reduced 20.02%	443,021 $797,000
Q3 2017 Nov 09, 2017	BUY	$1.99 - $2.65 $1.1 Million - $1.47 Million	553,937	553,937 $1.21 Million

Others Institutions Holding GERN

# of Institutions

307

Shares Held

465M

Call Options Held

1.07M

Put Options Held

648K

View Full List

About GERON CORP

Ticker GERN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 377,819,008
Market Cap $642M
Description
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hemat...

More about GERN

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account